Zobrazeno 1 - 10
of 566
pro vyhledávání: '"E Cutler"'
Publikováno v:
South African Medical Journal, Vol 113, Iss 10 (2023)
Background. Point-of-care (POC) rapid recency testing can be used as a cost-effective tool to identify recently infected individuals (i.e. infected within the last 12 months) in near-real time, support epidemic control and identify hotspots for trans
Externí odkaz:
https://doaj.org/article/629738d6ec2c46b3bb492b98b12e72a7
Autor:
Ricardo Ribas, Sunil Pancholi, Aradhana Rani, Eugene Schuster, Stephanie K. Guest, Joanna Nikitorowicz-Buniak, Nikiana Simigdala, Allan Thornhill, Francesca Avogadri-Connors, Richard E. Cutler, Alshad S. Lalani, Mitch Dowsett, Stephen R. Johnston, Lesley-Ann Martin
Publikováno v:
Breast Cancer Research, Vol 20, Iss 1, Pp 1-15 (2018)
Abstract Background Endocrine therapies are the mainstay of treatment for oestrogen receptor (ER)-positive (ER+) breast cancer (BC). However, resistance remains problematic largely due to enhanced cross-talk between ER and growth factor pathways, cir
Externí odkaz:
https://doaj.org/article/d144720f2d924e96b49640bc5c504a90
Autor:
Carlos L. Arteaga, Jens Meiler, Christine M. Lovly, Darren Cross, Alshad S. Lalani, Richard E. Cutler, Vincent Miller, Jie He, David B. Solit, David M. Hyman, Michael F. Berger, Richard Lanman, Rebecca Nagy, Gregory R. Sliwoski, James P. Koch, Jonathan H. Sheehan, Monica Red Brewer, Ariella B. Hanker
Supplementary Figure S1. HER2L869R and HER3E928G cooperate to drive ERBB signaling output. Supplementary Figure S2. MG132 treatment restores expression of HER2T798I.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::154dda147285a5c156d4cbf8d35fdb31
https://doi.org/10.1158/2159-8290.22531999.v1
https://doi.org/10.1158/2159-8290.22531999.v1
Autor:
Carlos L. Arteaga, Jens Meiler, Christine M. Lovly, Darren Cross, Alshad S. Lalani, Richard E. Cutler, Vincent Miller, Jie He, David B. Solit, David M. Hyman, Michael F. Berger, Richard Lanman, Rebecca Nagy, Gregory R. Sliwoski, James P. Koch, Jonathan H. Sheehan, Monica Red Brewer, Ariella B. Hanker
Supplementary Table S1. Summary of mutations identified by FoundationOne profiling of the original, pre-neratinib skin metastasis. Supplementary Table S2. Frequency of HER2L869R and HER2T798I mutations. Supplementary Table S3. Sequencing of plasma DN
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8f218f8081ab31c8a70d37c3929898c2
https://doi.org/10.1158/2159-8290.22531996.v1
https://doi.org/10.1158/2159-8290.22531996.v1
Autor:
Carlos L. Arteaga, Alan Auerbach, Richard Bryce, Alshad S. Lalani, Richard E. Cutler, Francesca Avogadri-Connors, Justin M. Balko, Melinda Sanders, Paula I. González Ericsson, Sarah Croessmann, Mellissa J. Nixon, Luigi Formisano, Angel Guerrero-Zotano, Luis J. Schwarz, Dhivya R. Sudhan
Purpose:The phase III ExteNET trial showed improved invasive disease-free survival in patients with HER2+ breast cancer treated with neratinib versus placebo after trastuzumab-based adjuvant therapy. The benefit from neratinib appeared to be greater
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ccdef9da4b82af81bb809312ab12ea87
https://doi.org/10.1158/1078-0432.c.6529268.v1
https://doi.org/10.1158/1078-0432.c.6529268.v1
Autor:
Carlos L. Arteaga, Nick V. Grishin, Richard B. Lanman, Vincent A. Miller, Alshad S. Lalani, Richard E. Cutler, Jie He, Massimo Cristofanilli, Eric H. Bernicker, Aju Mathew, Rebecca J. Nagy, Dhivya R. Sudhan, Paula I. Gonzalez-Ericsson, Lisa N. Kinch, Luigi Formisano, Sarah Croessmann
Table S1 - HER2 mutations Fig S1 - HER2 co-occur Fig S2 - Long Term Fulv. Fig S3 - L755S CI index Fig S4 - L755S RTprofile Fig S5 - Prot Align Fig S6 - Drug Assays Fig S7 - Quant of Drug Fig S8-11 - immunoblot Fig S12 - L755S mouse Fig S13 - S6 IHC -
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c53a2007a6aaecf8802c539e54e9801
https://doi.org/10.1158/1078-0432.22474497
https://doi.org/10.1158/1078-0432.22474497
Autor:
Carlos L. Arteaga, Nick V. Grishin, Richard B. Lanman, Vincent A. Miller, Alshad S. Lalani, Richard E. Cutler, Jie He, Massimo Cristofanilli, Eric H. Bernicker, Aju Mathew, Rebecca J. Nagy, Dhivya R. Sudhan, Paula I. Gonzalez-Ericsson, Lisa N. Kinch, Luigi Formisano, Sarah Croessmann
Purpose:We examined the role of ERBB2-activating mutations in endocrine therapy resistance in estrogen receptor positive (ER+) breast cancer.Experimental Design:ERBB2 mutation frequency was determined from large genomic databases. Isogenic knock-in E
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::076dd429e25d3c11cb69e0237b39aeaa
https://doi.org/10.1158/1078-0432.c.6528801.v1
https://doi.org/10.1158/1078-0432.c.6528801.v1
Autor:
Carlos L. Arteaga, Alan Auerbach, Richard Bryce, Alshad S. Lalani, Richard E. Cutler, Francesca Avogadri-Connors, Justin M. Balko, Melinda Sanders, Paula I. González Ericsson, Sarah Croessmann, Mellissa J. Nixon, Luigi Formisano, Angel Guerrero-Zotano, Luis J. Schwarz, Dhivya R. Sudhan
Supplementary figure files
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c7717b0f2dff6e0436730482ee3aeda
https://doi.org/10.1158/1078-0432.22476023
https://doi.org/10.1158/1078-0432.22476023
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Nicholas W. Thompson, Alexis Maldonado, Theresa E. Cutler, Holly R. Trellue, Kelsey M. Amundson, Venkateswara Rao Dasari, Joetta M. Goda, Travis J. Grove, David K. Hayes, Jesson D. Hutchinson, Hadyn M. Kistle, Cole M. Kostelac, Juliann R. Lamproe, Christopher Matthews, George McKenzie, Garrett E. McMath, Alexander T. McSpaden, Rene G. Sanchez, Kristin N. Stolte, Jessie L. Walker, Robert Weldon, Nicholas H. Whitman
Publikováno v:
Frontiers in Energy Research. 10
The National Criticality Experiments Research Center (NCERC) located at the Nevada National Security Site (NNSS) in the Device Assembly Facility (DAF) and operated by Los Alamos National Laboratory (LANL) is the only general purpose critical experime
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::850ae0d34c0cc92789071872b5bbb1f8
https://doi.org/10.3389/fenrg.2022.1082389
https://doi.org/10.3389/fenrg.2022.1082389